Summit Therapeutics plc Summit Announces Management Update

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Announces Management Update 
 
   Oxford, UK, and Cambridge, MA, US, 24 January 2020 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David 
Roblin has resigned as Chief Operating Officer, Chief Medical Officer 
and President of R&D, effective 31 January 2020. 
 
   "David has been instrumental in establishing our leadership position in 
new mechanism antibiotic development and launching our Phase 3 clinical 
trials of ridinilazole for the treatment of C. difficile infection," 
said Mr Glyn Edwards, Chief Executive Officer of Summit. "We are 
grateful to David for building a strong team that will continue to 
advance Summit's important work and wish him all the very best in his 
future endeavours." 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014 (MAR). The person responsible for 
arranging for the release of this announcement on behalf of the Company 
is Richard Pye, Vice President, Investor Relations and Corporate 
Affairs. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)             Tel:               44 (0)1235 443 951 
Michelle Avery (US office)                                               +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:              +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson / Ludovico 
Lazzaretti 
 
N+1 Singer (Joint Broker)                          Tel:              +44 (0)20 7496 3000 
Aubrey Powell / George Tzimas, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)          Tel:              +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                                     Tel:                  +1 781 684 6552 
                                                              mailto:summit@mslgroup.com 
Erin Anthoine                                                        summit@mslgroup.com 
                                                          ------------------------------ 
 
Consilium Strategic Communications (UK)            Tel:              +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Sukaina Virji            mailto:summit@consilium-comms. 
                                                          com 
                                                          summit@consilium-comms.com 
                                                          ------------------------------ 
Lindsey Neville 
 
 
   Summit Forward-looking Statements 
 
   Any statements in this press release about the Company's future 
expectations, plans and prospects, including but not limited to, 
statements about changes in senior management, the potential benefits 
and future operation of the BARDA contract, including any potential 
future payments thereunder, the clinical and preclinical development of 
the Company's product candidates, the therapeutic potential of the 
Company's product candidates, the potential commercialisation of the 
Company's product candidates, the sufficiency of the Company's cash 
resources, the timing of initiation, completion and availability of data 
from clinical trials, the potential submission of applications for 
marketing approvals and other statements containing the words 
"anticipate," "believe," "continue," "could," "estimate," "expect," 
"intend," "may," "plan," "potential," "predict," "project," "should," 
"target," "would," and similar expressions, constitute forward-looking 
statements within the meaning of The Private Securities Litigation 
Reform Act of 1995. Actual results may differ materially from those 
indicated by such forward-looking statements as a result of various 
important factors, including: the ability of BARDA to terminate our 
contract for convenience at any time, the uncertainties inherent in the 
initiation of future clinical trials, availability and timing of data 
from ongoing and future clinical trials and the results of such trials, 
whether preliminary results from a clinical trial will be predictive of 
the final results of that trial or whether results of early clinical 
trials or preclinical studies will be indicative of the results of later 
clinical trials, expectations for regulatory approvals, laws and 
regulations affecting government contracts and funding awards, 
availability of funding sufficient for the Company's foreseeable and 
unforeseeable operating expenses and capital expenditure requirements 
and other factors discussed in the "Risk Factors" section of filings 
that the Company makes with the Securities and Exchange Commission, 
including the Company's Annual Report on Form 20-F for the fiscal year 
ended 31 January 2019. Accordingly, readers should not place undue 
reliance on forward-looking statements or information. In addition, any 
forward-looking statements included in this press release represent the 
Company's views only as of the date of this release and should not be 
relied upon as representing the Company's views as of any subsequent 
date. The Company specifically disclaims any obligation to update any 
forward-looking statements included in this press release. 
 
   -END-
(END) Dow Jones Newswires
January 24, 2020 07:00 ET (12:00 GMT)
Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025